Techniques and Innovations in Flap Engineering: A Review
Kouniavski E., Egozi D., Wolf Y.
Laboratory Study, published in Plast Reconstr Surg Glob Open (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Plast Reconstr Surg Glob Open (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 36168612
- PMCID
- PMC9509183
- DOI
- 10.1097/gox.0000000000004523
- Citations
- 7
Abstract (original English)
Currently, the gold standard for complex defect reconstruction is autologous tissue flaps, with vascularized composite allografts as its highest level. Good clinical results are obtained despite considerable obstacles, such as limited donor sites, donor site morbidity, and complex operations. Researchers in the field of tissue engineering are trying to generate novel tissue flaps requiring small or no donor site sacrifice. At the base of existing technologies is the tissue's potential for regeneration and neovascularization. Methods A review was conducted identifying relevant published articles in PubMed on the subject of flap engineering, with the focus on plastic surgery. This review article surveys contemporary technologies in flap engineering, including cell sheet technology, prefabricated flaps, and tissue engineering chambers. Conclusions Some of the described procedures, though not yet ready for clinical use, are certainly ready for trial in large animal models and even human studies. Tissue engineering is a promising field for the handling of large and complex tissue defects.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.